Zynerba Pharma Revenue, Profits - ZYNE Quarterly Income Statement

Add to My Stocks
$9.31 $0.08 (0.85%) ZYNE stock closing price Mar 20, 2018 (Closing)

Fundamental analysis of ZYNE stock involves analyzing its financial statements, apart from checking the Zynerba Pharma stock price. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from - to - and how operating and non operating activities have impacted the ZYNE stock. The Zynerba Pharma profit and loss statement for 2017 Q3 shows a net profit of $-8.31M. Profits for last year was $-8.32M. Apart from this an investor should also check Zynerba Pharma assets and Zynerba Pharma free cash flow.

View and download details of revenue and profits for Zynerba Pharma for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Zynerba Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)---------
Zynerba Pharma Gross Profit
Research & Development Expense5.75M5.73M5.49M4.92M4.5M4.8M2.56M3.31M2.27M
Selling General & Admin Expense2.79M2.63M2.21M1.79M1.49M1.47M1.68M2.16M1.92M
Income Before Depreciation Depletion Amortization-8.54M-8.36M-7.7M-6.69M-5.99M-6.28M-4.24M-5.43M-3.99M
Depreciation Depletion Amortization---------
Non Operating Income----0.2M---0.01M--
Interest Expense---------
Zynerba Pharma Pretax Income
Provision for Income Taxes------0.05M---
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-8.31M-8.32M-7.26M-6.9M-5.98M-6.23M-4.28M-5.44M-3.99M
Extraordinary Items & Discontinued Operations---------
Zynerba Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS13.1M13.05M12.07M9.68M8.91M8.86M8.82M8.79M6.05M
Average Shares used to compute Basic EPS13.1M13.05M12.07M9.68M8.91M8.86M8.82M8.79M6.05M
Income Before Nonrecurring Items-8.31M-8.32M-7.26M-6.9M-5.98M-6.23M-4.28M-5.44M-3.49M
Income from Nonrecurring Items---------0.5M
Zynerba Pharma Earnings Per Share Basic Net
Zynerba Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.63-0.64-0.60-0.71-0.67-0.70-0.49-0.62-0.58
Preferred Dividends Acc Pd---------
Dividends Common0.00--------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Click here to view our Pfizer financial analysis

It is very helpful to read a report on Zynerba Pharma stock analysis. An investor must check the following items in an income statement:

  • Topline: A growing topline, as seen from the Zynerba Pharma revenue chart, as isn't the case with Zynerba Pharma indicates a sagging business. One needs to compare the QoQ topline or sales growth of ZYNE stock with its peers like AQXP stock and SLGL stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-8.31M for Zynerba Pharma for 2017 Q3. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the ZYNE income statement, one can check the Zynerba Pharma historical stock prices to check how the price has moved with time.

Zynerba Pharma Income Statement - Key Financial Ratios

Operating Margin
Net Profit Margin